Summary
This study investigated changes and the time course of these changes in renal function in children following treatment with carboplatin, and identified risk factors for nephrotoxicity. Glomerular and proximal renal tubular function were investigated before and up to 2 years after treatment in 23 children who received carboplatin. The main findings were reduced glomerular filtration rate (GFR), and increased renal tubular loss of magnesium, manifested by a low serum magnesium (S Mg). The mean fall in GFR was 22 ml min–1 1.73 m–2 (P = 0.012), and in S Mg it was 0.17 mmol l–1 (P = 0.0077). No patient had a clinically important reduction in GFR, and only one patient had symptomatic hypomagnesaemia. GFR and S Mg did not change over time after completion of treatment. Cumulative dose (CD) of carboplatin was inversely related to mean S Mg at the end of treatment (P = 0.031), and directly related to the fall in S Mg (P < 0.001). Calculated cumulative area under the plasma concentration versus time curve (AUC) of carboplatin was inversely related to S Mg after treatment (P = 0.004). Dose intensity (DI) of carboplatin was not shown to be related to S Mg following treatment. CD, AUC and DI of carboplatin were not related to GFR, nor change in GFR, after treatment. High CDs of carboplatin may be associated with evidence of renal damage qualitatively similar to but less severe than that caused by cisplatin. GFR and SMg should be carefully monitored when high CDs of carboplatin are used, or if carboplatin is combined with other nephrotoxic chemotherapy.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bitran, JD, Desser, RK, Billings, AA, Kozloff, MF & Shapiro, CM (1982). Acute nephrotoxicity following cis-dichlorodiammine-platinum. Cancer 49: 1784–1788.
Brandt, LJ & Broadbent, V (1993). Nephrotoxicity following carboplatin use in children: is routine monitoring of renal function necessary?. Med Pediatr Oncol 21: 31–35.
Brock, PR, Koliouskas, DE, Barratt, TM, Yeomans, E & Pritchard, J (1991). Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 118: 531–534.
Broun, ER, Nichols, CR, Einhorn, LH & Tricot, GJ (1991). Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer 68: 1513–1515.
Buckley, JE, Clark, VL, Meyer, TJ & Pearlman, NW (1984). Hypomagnesemia after cisplatin combination chemotherapy. Arch Int Med 144: 2347–2348.
Castel, V, Badal, M, Bezanilla, J, Llombart, A, Ruiz-Jiménez, J, Sánchez de Toledo, J, Melero, C & Mulet, M (1995). Treatment of stage III neuroblastoma with emphasis on intensive induction chemotherapy: a report from the Neuroblastoma Group of the Spanish Society of Pediatric Oncology. Med Pediatr Oncol 24: 29–35.
Castello, MA, Clerico, A, Jenkner, A & Dominici, C (1990). A pilot-study of high-dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors. Pediatr Hematol Oncol 7: 129–135.
Corbett, R, Pinkerton, C, Pritchard, J, Meller, S, Lewis, I, Kington, J & McElwain, T (1992). Pilot study of high dose vincristine, etoposide, carboplatin and high dose melphalan with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer 28A: 1324–1328.
de Camargo, B, Melaragno, R, Silva, NSE, Mendonca, N, Alvares, MN, Morinaka, E, Marques, A & Cusato, MP (1994). Phase II study of carboplatin as a single drug for relapsed Wilms’ tumor: experience of the Brazilian Wilms’ Tumor Study Group. Med Pediatr Oncol 22: 258–260.
Doz, F & Pinkerton, R (1994). What is the place of carboplatin in paediatric oncology?. Eur J Cancer 30A: 194–201.
Elias, AD, Ayash, LJ, Eder, JP, Wheeler, C, Deary, J, Weissman, L, Schryber, S, Hunt, M, Critchlow, J & Schnipper, L et al (1991). A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol 9: 320–327.
Ettinger, LJ, Gaynon, PS, Krailo, MD, Ru, N, Baum, ES, Siegel, SE & Hammond, GD (1994). A phase II study of carboplatin in children with recurrent or progressive solid tumors. Cancer 73: 1297–1301.
Flombaum, CD (1984). Hypomagnesemia associated with cisplatin combination chemotherapy. Arch Int Med 144: 2336–2337.
Frappaz, D, Michon, J, Hartmann, O, Bouffet, E, Lejars, O, Rubie, H, Gentet, JC, Chastagner, P, Sariban, E & Brugiere, L et al (1992). Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study. J Clin Oncol 10: 1592–1601.
Frenkel, J, Kool, G & de Kraker, J (1995). Acute renal failure in high dose carboplatin therapy. Med Pediatr Oncol 25: 473–474.
Gordon, SJ, Pearson, AD, Reid, MM & Craft, AW (1992). Toxicity of single-day high-dose vincristine, melphalan, etoposide and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer 28A: 1319–1323.
Goren, MP, Forastiere, AA & Wright, RK et al (1987). Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. Cancer Chemother Pharmacol 19: 57–60.
Hardy, J, Tan, S, Fryatt, I & Wiltshaw, E (1990). How nephrotoxic is carboplatin?. Br J Cancer 61: 644
Hill, JB & Russo, A (1981). Cisplatin-induced hypomagnesemic hypocalcemia [letter]. Arch Int Med 141: 1100–1101.
Lashford, LS, Campbell, RH, Gattamaneni, HR, Robinson, K, Walker, D & Bailey, C (1996). An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children. Arch Dis Child 74: 219–223.
McDonald, BR, Kirmani, S, Vasquez, M & Mehta, RL (1991). Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature. Am J Med 90: 386–391.
Marina, NM, Rodman, J, Shema, SJ, Bowman, LC, Douglass, E, Furman, W, Santana, VM, Hudson, M, Wilimas, J, Meyer, W, Madden, T & Pratt, C (1993). Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumours. J Clin Oncol 11: 554–560.
Mason, MD, Nicholls, J & Horwich, A (1991). The effect of carboplatin on renal function in patients with metastatic germ cell tumours. Br J Cancer 63: 630–633.
Newell, DR, Pearson, AD, Balmanno, K, Price, L, Wyllie, R, Keir, M, Calvert, AH, Lewis, IJ, Pinkerton, CR & Stevens, MC (1993). Carboplatin pharmacokinetics in children: the development of a paediatric dosing formula. J Clin Oncol 11: 2314–2323.
Nichols, CR, Andersen, J, Lazarus, HM, Fisher, H, Greer, J, Stadtmauer, EA, Loehrer, PJ & Trump, DL (1992). High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol 10: 558–563.
Pinkerton, C, Broadbent, V, Horwitch, A, Levitt, J, McElwain, T, Meller, S, Mott, M, Oakhill, A & Pritchard, J (1990). “JEB” – a carboplatin based regimen for malignant germ cell tumours in children. Br J Cancer 62: 257–262.
Salem, P, Khalyl, M, Jabboury, K & Hashimi, L (1984). Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity. Cancer 53: 837–840.
Shea, TC, Flaherty, M, Elias, A, Eder, JP, Antman, K, Begg, C, Schnipper, L, Frei, E3 & Henner, WD (1989). A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support [published erratum appears in J Clin Oncol 1989 7: 1177]. J Clin Oncol 7: 651–661.
Shea, TC, Storniolo, AM, Mason, JR, Newton, B, Mullen, M, Taetle, R & Green, MR (1992). A dose-escalation study of carboplatin/cyclophosphamide/etoposide along with autologous bone marrow or peripheral blood stem cell rescue. Semin Oncol 19: 139–144.
Siegert, W, Beyer, J, Strohscheer, I, Baurmann, H, Oettle, H, Zingsem, J, Zimmermann, R, Bokemeyer, C, Schmoll, HJ & Huhn, D (1994). High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol 12: 1223–1231.
Skillen, AW, Buamah, PK, Cantwell, BM, Cornell, C, W, HA & Harris, AL (1988). Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9). Cancer Chemother Pharmacol 22: P 228–P 234.
Skinner, R, Pearson, A, Price, L, Coulthard, M & Craft, A (1991a). Renal function after carboplatin in children. Med Pediatr Oncol 19: 344
Skinner, R, Pearson, ADJ, Coulthard, MG, Skillen, AW, Hodson, AW, Goldfinch, ME, Gibb, I & Craft, AW (1991b). Assessment of chemotherapy-related nephrotoxicity in children with cancer. Cancer Chemother Pharmacol 28: 81–92.
Sleijfer, DT, Smit, EF, Meijer, S, Mulder, NH & Postmus, PE (1989). Acute and cumulative effects of carboplatin on renal function. Br J Cancer 60: 116–120.
Stevens, M, Lewis, I, AJ, P & Pinkerton, C (1991). Carboplatin and renal function in children. Br J Cancer 63: 158
Tscherning, C, Rubie, H, Chanchole, A, Claeyssens, S, Robert, A, Fabre, J & Bouissou, F (1994). Recurrent renal salt wasting in a child treated with carboplatin and etoposide. Cancer 73: 1761–1763.
Wilson, WH, Jain, V, Bryant, G, Cowan, KH, Carter, C, Cottler, FM, Goldspiel, B, Steinberg, SM, Longo, DL & Wittes, RE (1992). Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 10: 1712–1722.
Womer, RB, Pritchard, J & Barrat, TM (1985). Renal toxicity of cisplatin in children. J Pediatr 106: 659–653.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
English, M., Skinner, R., Pearson, A. et al. Dose-related nephrotoxicity of carboplatin in children. Br J Cancer 81, 336–341 (1999). https://doi.org/10.1038/sj.bjc.6690697
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690697
Keywords
This article is cited by
-
Association of expression of GADD family genes and apoptosis in human kidney proximal tubular (HK-2) cells exposed to nephrotoxic drugs
Molecular & Cellular Toxicology (2022)
-
Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance
Pediatric Nephrology (2018)
-
Late effects of chemotherapeutic agents on renal function in childhood cancer survivors: a review of the literature
Irish Journal of Medical Science (1971 -) (2017)
-
Estimation of calcium, magnesium, cadmium, and lead in biological samples from paralyzed quality control and production steel mill workers
Environmental Monitoring and Assessment (2015)